The statement provides information for healthcare providers on genetic testing, including risks and benefits, as patients may require testing to help confirm a diagnosis or guide therapy.

The statement discusses the importance of genetic counseling before and after genetic testing and outlines potential limitations of testing in dyslipidemia. It also has a detailed table of recommendations to guide healthcare professionals.

The article, "Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association," is in press with the Journal of Clinical Lipidology and can be accessed through the journal or on the NLA website.

LexaGene to unveil rapid multipathogen genetic test this fall
Molecular diagnostics company LexaGene has announced that its MiQLab automated genetic analyzer for rapid pathogen detection will make its commercial...

Group calls for consistent use of genetic cancer terms
A consortium of cancer patient advocacy groups and other stakeholders has recommended uniform use of common terms for biomarker and germline genetic testing...

Illumina introduces sequencing software for rare genetic diseases
Illumina has launched software that facilitates whole genome sequencing for rapid identification of rare genetic diseases.

Next-generation sequencing reveals inherited mutations in young cancer patients
Researchers advocated for increased genomic surveillance in younger adult cancer patients with tumors that typically strike later in life, in a study...